A PHASE 2/3 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FPI-2265 (225AC-PSMA-I&T) IN PATIENTS WITH PSMA-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY TREATED WITH 177LUPSMA RADIOLIGAND THERAPY (RLT)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Prostate Cancer
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male
  • Other Inclusion Criteria:
    1. Diagnosis of adenocarcinoma of prostate proven by histopathology
    2. Must have been previously treated with lutetium-PSMA therapy (lutetium-177 vipivotide tetraxetan or other lutetium-177-PSMA RLT)
    3. Participants with known BRCA mutations should have received FDA-approved therapies such as PARP inhibitors

You may not be eligible for this study if the following are true:

    1. Previous treatment with any of the following within six months of the first dose of study treatment: samarium-153, rhenium-186, rhenium-188, RADIUM-223, hemi-body irradiation
    2. Participants who received more than two prior lines of cytotoxic chemotherapy for CRPC
    3. Participants with known, unresolved urinary tract obstruction



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.